Drug Patents owned by Nabriva

1. Drug name - XENLETA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153689 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Mar, 2028

(5 years from now)

US8071643 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Jan, 2029

(6 years from now)

US9120727 NABRIVA Process for the preparation of pleuromutilins
May, 2031

(8 years from now)

CN105111117A NABRIVA Process Of Preparing Pleuromutilin
Apr, 2017

(5 years ago)

CN101668738B NABRIVA Truncated Side Pleuromutilin Derivative Used For Treating Microorganism-Mediated Disease
Mar, 2028

(5 years from now)

CN104211624A NABRIVA Truncated Side Pleuromutilin Derivative Used For Treating Microorganism-Mediated Disease
Mar, 2028

(5 years from now)

CN101668738A NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

CN104211624B NABRIVA For The Treatment Of Diseases Mediated By Microbes Of The Pleuromutilin Derivative
Mar, 2028

(5 years from now)

CN103080083B NABRIVA Process Of Preparing Pleuromutilin
May, 2031

(8 years from now)

CN103080083A NABRIVA Process For The Preparation Of Pleuromutilins
May, 2031

(8 years from now)

IN200905818P1 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

IN273636B NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

IN387806B NABRIVA Process For The Preparation Of Pleuromutilins
May, 2031

(8 years from now)

IN201918036510A NABRIVA Process For The Preparation Of Pleuromutilins
May, 2031

(8 years from now)

EP2380874B1 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

EP2380874A2 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

EP2380874A3 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

EP2137143B1 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

EP2137143A1 NABRIVA Pleuromutilin Derivatives For The Treatment Of Diseases Mediated By Microbes
Mar, 2028

(5 years from now)

EP3299356B1 NABRIVA Process For The Preparation Of Pleuromutilins
May, 2031

(8 years from now)

EP2576505B1 NABRIVA Crystalline Form Of A Pleuromutilin
May, 2031

(8 years from now)

EP2576505A1 NABRIVA Crystalline Form Of A Pleuromutilin
May, 2031

(8 years from now)

EP3299356A1 NABRIVA Process For The Preparation Of Pleuromutilins
May, 2031

(8 years from now)

Drugs and Companies using LEFAMULIN ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE/15ML (EQ 10MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.